Background and Objectives Time Frame
A global pharmaceutical company wanted to strengthen its portfolio in emerging markets and engaged SmartAnalyst to:

  • Generate asset opportunities available for potential partnering
  • Develop a list of attractive indications within the GI, Oncology, and Diabetes therapy areas
  • Identify external opportunity set within attractive indications, which are aligned to the client’s strategy across the emerging markets
20 weeks
Approach and Recommendations (Methodology) Results
A two-phased approach was adopted to identify potential assets for each therapy area (GI, Oncology, and Diabetes)

Phase I: Identification and Shortlisting of Indications and Assets

  • Long list of potential assets (Asset Universe) was created and high-level filters were applied to narrow down to an actionable set (short list) of assets
  • Shortlisted assets (GI – 41 assets; Oncology – 6 assets; Diabetes – 21 assets) were bucketed by indication, and attractiveness of indication was determined based on epidemiology, unmet needs, and competitive intensity

Phase II: Asset Prioritization

  • Shortlisted assets were prioritized based on pre-defined criteria and client strategic considerations
  • Prioritized assets (GI – 9 assets; Oncology – 6 assets) were profiled and evaluated on the basis of therapeutic and commercial potential and availability for partnership; in Diabetes, all 21 assets shortlisted were profiled based on commercial and scientific attractiveness
Identified opportunities aligned to the client’s strategic needs and created detailed profiles of the prioritized set of assets in GI, Oncology and Diabetes space to inform and support partnering discussions